| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. (ACRS) has 6 insiders with recent SEC Form 4 filings, including 4 buys and 17 sells. ACRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.95M | $66.75M | - | |
| Other | 510.0K | $2.44M | - | |
| COO | 336.3K | $1.61M | - | |
| CEO | 274.8K | $1.31M | - | |
| Other | 18.7K | $89.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2021 | Walker Neal85 | President And CEO | Sell | 30,000 | $26.84 | $805,239.00 | -2.5% | -41.1% | -43.6% | |
| Jun 27, 2019 | Flynn James E62 | 10% Owner | Sell | 699,475 | $2.69 | $1,882,077.38 | -14.5% | - | - | |
| Jun 26, 2019 | Flynn James E62 | 10% Owner | Sell | 1,704 | $4.50 | $7,670.56 | - | - | - | |
| Jun 25, 2019 | Flynn James E62 | 10% Owner | Sell | 454,261 | $4.59 | $2,085,238.18 | -3.0% | - | - | |
| May 10, 2019 | Flynn James E62 | 10% Owner | Sell | 614,710 | $6.13 | $3,765,521.64 | -5.4% | - | - | |
| Oct 22, 2018 | Mehra Anand | Director | Buy | 372,093 | $10.75 | $3,999,999.75 | +24.2% | - | - | |
| Oct 4, 2018 | Tullman Stephen A. | Director | Buy | 7,100 | $14.00 | $99,370.18 | +4.2% | - | - | |
| Aug 23, 2018 | Tullman Stephen A. | Director | Buy | 6,600 | $15.00 | $98,984.82 | +4.0% | - | - | |
| Aug 15, 2018 | Tullman Stephen A. | Director | Buy | 6,250 | $15.97 | $99,812.50 | +4.0% | - | - | |
| Jun 12, 2018 | Ali-Jackson Kamil71 | Chief Legal Officer | Sell | 5,000 | $20.00 | $100,000.00 | -3.0% | - | - |